[PDF][PDF] Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin
CG Park, H Lee, JW Choi, SJ Lee, SH Kim… - Int J Clin Pharmacol …, 2010 - researchgate.net
Objectives: To explore if nonconcurrent amlodipine dosing results in less drug interaction,
the pharmacokinetic profiles, safety and efficacy endpoints were assessed following …
the pharmacokinetic profiles, safety and efficacy endpoints were assessed following …
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine …
FD Richard Hobbs - Vascular health and risk management, 2007 - Taylor & Francis
In order to prevent cardiovascular events, it is essential to effectively manage overall risk of
cardiovascular disease. However, despite guideline recommendations to this effect, current …
cardiovascular disease. However, despite guideline recommendations to this effect, current …
Pharmacokinetic and Safety Profiles of a Fixed‐Dose Combination of Amlodipine, Valsartan, and Atorvastatin: A 3‐Period Replicate Crossover Study
S Kim, JW Ko, JR Kim - Clinical Pharmacology in Drug …, 2020 - Wiley Online Library
The objective of study was to compare the pharmacokinetic and safety profiles of a fixed‐
dose combination (FDC) formulation of 5/160/20 mg amlodipine/valsartan/atorvastatin with …
dose combination (FDC) formulation of 5/160/20 mg amlodipine/valsartan/atorvastatin with …
A combination of amlodipine and atorvastatin in cardiovascular risk reduction
D Dedov, N Mukallov, I Evtyukhln - Vrach, 2013 - vestnik.nvsu.ru
A COMBINATION OF AMLODIPINE AND ATORVASTATIN IN CARDIOVASCULAR RISK
REDUCTION - Dedov - Vrach English Русский 简体中文 Eco-vector Vrach ISSN 0236-3054 (Print) …
REDUCTION - Dedov - Vrach English Русский 简体中文 Eco-vector Vrach ISSN 0236-3054 (Print) …
[HTML][HTML] A randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and the tolerability of a triple combination of amlodipine/losartan …
Purpose The objective of this study was to evaluate the efficacy and tolerability of a triple
combination of amlodipine/losartan/rosuvastatin in patients with hypertension and …
combination of amlodipine/losartan/rosuvastatin in patients with hypertension and …
Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and amlodipine/atorvastatin fixed combination
F Aslam, A Haque, V Lee, JA Foody - Patient preference and …, 2009 - Taylor & Francis
Cardiovascular disease (CVD) accounts for in excess of 930,000 deaths in the United States
each year. Risk factors for CVD often co-exist. Studies estimate that over half of the …
each year. Risk factors for CVD often co-exist. Studies estimate that over half of the …
Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease
JF Dorval, T Anderson, J Buithieu, S Chan… - The American journal of …, 2005 - Elsevier
The effects of combined atorvastatin and amlodipine on blood pressure (BP) and low-
density lipoprotein (LDL) cholesterol levels were investigated in 134 patients with …
density lipoprotein (LDL) cholesterol levels were investigated in 134 patients with …
Fixed‐dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia
CP Lin, YC Tung, FC Hsiao, CH Yang… - The Journal of …, 2020 - Wiley Online Library
Hypertension and dyslipidemia are important risk factors for cardiovascular disease.
However, the clinical outcomes of fixed‐dose combination (FDC) versus free‐equivalent …
However, the clinical outcomes of fixed‐dose combination (FDC) versus free‐equivalent …
P-241 MP-30: Safety and tolerability of coadministered amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia in the respond study
RA Preston, F Sun, L Tarasenko - American Journal of …, 2005 - search.proquest.com
Amlodipine/atorvastatin combination therapy has been demonstrated to be an effective
approach for the management of concomitant hypertension (HTN) and dyslipidemia (DYS) …
approach for the management of concomitant hypertension (HTN) and dyslipidemia (DYS) …
[引用][C] How we treat patients with cardiovascular diseases in real clinical practice
B IuN, M VIu - Terapevticheskii arkhiv, 2003 - europepmc.org
Can combining different risk interventions into a single formulation contribute to improved
cardiovascular disease risk reduction? Rationale and design for an international, open-label …
cardiovascular disease risk reduction? Rationale and design for an international, open-label …